Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xuejun Fan

Showing results (51-60 of 74) with videos related to

Pageof 8
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|March 22, 2015
Trastuzumab triggers phagocytic killing of high HER2 cancer cells in vitro and in vivo by interaction with Fcγ receptors on macrophagesYun Shi, Xuejun Fan, Hui Deng, et al.
Nanotechnology|September 5, 2019
High-performance humidity sensor using Schottky-contacted SnS nanoflakes for noncontact healthcare monitoringHongyu Tang, Yutao Li, Huaiyu Ye, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 31, 2015
Dysfunctional Antibodies in the Tumor Microenvironment Associate with Impaired Anticancer ImmunityNingyan Zhang, Hui Deng, Xuejun Fan, et al.
Cancer Research Communications|June 28, 2023
Adjuvant Therapy with Oncolytic Adenovirus Delta-24-RGDOX After Intratumoral Adoptive T-cell Therapy Promotes Antigen Spread to Sustain Systemic Antitumor ImmunityHong Jiang, Dong Ho Shin, Yanhua Yi, et al.
Breast Cancer Research : BCR|August 10, 2012
A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacyXuejun Fan, Randall J Brezski, Ming Fa, et al.
Molecular Cancer Therapeutics|January 2, 2015
A novel therapeutic strategy to rescue the immune effector function of proteolytically inactivated cancer therapeutic antibodiesXuejun Fan, Randall J Brezski, Hui Deng, et al.
Science Translational Medicine|September 7, 2022
A tetravalent TREM2 agonistic antibody reduced amyloid pathology in a mouse model of Alzheimer's diseasePeng Zhao, Yuanzhong Xu, LuLin Jiang, et al.
Oncotarget|February 25, 2016
Soluble Tie2 overrides the heightened invasion induced by anti-angiogenesis therapies in gliomasNahir Cortes-Santiago, Mohammad B Hossain, Konrad Gabrusiewicz, et al.
Antimicrobial Agents and Chemotherapy|October 18, 2017
Targeting Human-Cytomegalovirus-Infected Cells by Redirecting T Cells Using an Anti-CD3/Anti-Glycoprotein B Bispecific AntibodyWeixu Meng, Aimin Tang, Xiaohua Ye, et al.
Neuro-Oncology Advances|October 15, 2019
GITRL-armed Delta-24-RGD oncolytic adenovirus prolongs survival and induces anti-glioma immune memoryYisel Rivera-Molina, Hong Jiang, Juan Fueyo, et al.
Pageof 8

Showing results (51-60 of 74) with videos related to

Sort By:
Pageof 8
Journal of Immunology (Baltimore, Md. : 1950)|March 22, 2015
Trastuzumab triggers phagocytic killing of high HER2 cancer cells in vitro and in vivo by interaction with Fcγ receptors on macrophagesYun Shi, Xuejun Fan, Hui Deng, et al.
Nanotechnology|September 5, 2019
High-performance humidity sensor using Schottky-contacted SnS nanoflakes for noncontact healthcare monitoringHongyu Tang, Yutao Li, Huaiyu Ye, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 31, 2015
Dysfunctional Antibodies in the Tumor Microenvironment Associate with Impaired Anticancer ImmunityNingyan Zhang, Hui Deng, Xuejun Fan, et al.
Cancer Research Communications|June 28, 2023
Adjuvant Therapy with Oncolytic Adenovirus Delta-24-RGDOX After Intratumoral Adoptive T-cell Therapy Promotes Antigen Spread to Sustain Systemic Antitumor ImmunityHong Jiang, Dong Ho Shin, Yanhua Yi, et al.
Breast Cancer Research : BCR|August 10, 2012
A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacyXuejun Fan, Randall J Brezski, Ming Fa, et al.
Molecular Cancer Therapeutics|January 2, 2015
A novel therapeutic strategy to rescue the immune effector function of proteolytically inactivated cancer therapeutic antibodiesXuejun Fan, Randall J Brezski, Hui Deng, et al.
Science Translational Medicine|September 7, 2022
A tetravalent TREM2 agonistic antibody reduced amyloid pathology in a mouse model of Alzheimer's diseasePeng Zhao, Yuanzhong Xu, LuLin Jiang, et al.
Oncotarget|February 25, 2016
Soluble Tie2 overrides the heightened invasion induced by anti-angiogenesis therapies in gliomasNahir Cortes-Santiago, Mohammad B Hossain, Konrad Gabrusiewicz, et al.
Antimicrobial Agents and Chemotherapy|October 18, 2017
Targeting Human-Cytomegalovirus-Infected Cells by Redirecting T Cells Using an Anti-CD3/Anti-Glycoprotein B Bispecific AntibodyWeixu Meng, Aimin Tang, Xiaohua Ye, et al.
Neuro-Oncology Advances|October 15, 2019
GITRL-armed Delta-24-RGD oncolytic adenovirus prolongs survival and induces anti-glioma immune memoryYisel Rivera-Molina, Hong Jiang, Juan Fueyo, et al.
Pageof 8